Search results
Results from the WOW.Com Content Network
Johnson & Johnson On April 1, 2020, Johnson & Johnson stock was trading for $150 per share. In mid-July 2021, it’s up to $169, which is close to its 52-week high of $173.65.
For the fiscal year 2023, Johnson & Johnson reported earnings of $35.15 billion, with an annual revenue of $85.16 billion, an increase of 10.57% over the previous fiscal cycle. Johnson & Johnson's shares traded at over $160 per share, and its market capitalization was valued at over $386.7 billion in July 2024. [125]
Cerenovus Large Bore Catheter [10] Cerenovus Nimbus [11] Cerebase DA Guide Sheath [12] Trufill n-BCA Liquid Embolic System [13] Orthopedics (DePuy Synthes) Velys Digital Surgery platform [14] Attune Cementless Fixed Bearing Knee [15] Actis Hip Stem [16] Inhance Shoulder System [17] Dynatape Suture [18] Trumatch Graft Cage [19] Symphony OCT ...
J&JPRD was created in 2001 through the merging of various research organizations including McNeil Pharmaceuticals, Janssen Research Foundation, Three Dimensional Pharmaceuticals, and the R. W. Johnson Pharmaceutical Research Institute.
In September 2016, pharmaceutical and medical device company Johnson & Johnson announced they were buying Abbott Medical Optics for $4.3 billion. [13] On February 27, 2017, Abbott Medical Optics changed its name to Johnson & Johnson Vision following its $4.3 billion acquisition by Johnson & Johnson. [14] In 2017, JJV acquired TearScience. [15]
In Johnson Controls' first fiscal quarter of 2014 it posted a 5% increase in sales to $10.9 billion. The company's segment Why Would Johnson Controls' Share Price Drop After a Surge in Earnings?
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.
In March 2021, Johnson & Johnson and Aspen Pharmacare made a deal to manufacture 220 million vaccines at Aspen's Gqeberha facility in Eastern Cape, South Africa. They plan to distribute the vaccine to other countries, mainly in Africa , and also through the COVID-19 Vaccines Global Access (COVAX) program.